By publishing this list, which has been drafted from stakeholder consultations underpinning the Regulatory Science Strategy to 2025, the Agency hopes to stimulate researchers and funding organisations to consider addressing these needs in their works and programmes.
- EAACI can have a direct impact on public health by helping the Agency to improve scientific guidelines and regulatory decision-making, therefore it is of extreme importance for our community to provide its valuable feedback to the following topics:
- - Catalysing the integration of science and technology in medicines development
- Driving collaborative evidence generation improving the scientific quality of evaluations
- Advancing patient-centred access to medicines in partnership with healthcare systems
- Addressing emerging health threats and availability/therapeutic challenges
- Enabling and leveraging research and innovation in regulatory science
- Catalysing the integration of science and technology in medicines development
- Driving collaborative evidence generation improving the scientific quality of evaluations
- Addressing emerging health threats and availability/therapeutic challenging
- Enabling and leveraging research and innovation in regulatory science.
We invite you to consult the full document here.
- - General comments regarding the regulatory science research needs (RSRN) list
- - Comments on a particular topic in the RSRN
- - Details of your planned research on a topic in the RSRN or existing work on a topic in the RSRN
- - Relevant research results concerning a topic in the RSRN
- - Recommendations on topics which are not in the current RSRN
2021 marks the 10 year anniversary of collaboration between EMA and Health Care Professionals societies. EAACI was designated as the HCP representative joining the HMA/EMA Big Data Steering Group, which is an extremely important step for EAACI's outreach.
We look forward to hearing from you,
Marek Jutel
EAACI President
Stefano Del Giacco
EAACI President Elect
Ioana Agache
EAACI Past President